Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients
Open accessPublished version of a preprint
The DOI matches its Crossref record; 56 of the 60 references it cites were found in a registry or an index.
Abstract
Background: Understanding the longitudinal trajectory of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies is crucial for diagnosis of prior infection and predicting future immunity. Methods: We conducted a longitudinal analysis of coronavirus disease 2019 convalescent patients, with neutralizing antibody assays and SARS-CoV-2 serological assay platforms using SARS-CoV-2 spike (S) or nucleocapsid (N) antigens. Results: Sensitivities of serological assays in diagnosing prior SARS-CoV-2 infection changed with time. One widely used commercial platform that had an initial sensitivity of >95% declined to 71% at 81–100 days after diagnosis. The trajectories of median binding antibody titers measured over approximately 3–4 months were not dependent on the use of SARS-CoV-2 N or S proteins as antigen. The median neutralization titer decreased by approximately 45% per month. Each serological assay gave quantitative antibody titers that were correlated with SARS-CoV-2 neutralization titers, but S-based serological assay measurements better predicted neutralization potency. Correlation between S-binding and neutralization titers deteriorated with time, and decreases in neutralization titers were not predicted by changes in S-binding antibody titers. Conclusions: Different SARS-CoV-2 serological assays are more or less well suited for surveillance versus prediction of serum neutralization potency. Extended follow-up should facilitate the establishment of appropriate serological correlates of protection against SARS-CoV-2 reinfection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“neutralizing antibody responses to SARS-CoV-2 peak within the first few weeks after symptom onset but seem to decay after this time, with a proportion of individuals losing detectable neutralizing antibodies within months after infection5”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High concentrations of neutralising antibodies targeting the SARS-CoV-2 spike protein offer considerable protection against SARS-CoV-2 reinfection, supported by data from common human coronaviruses and non-human primate models and vaccine studies.”
From SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SARS-CoV-2 infection rapidly elicits nAbs (16, 21–24) that decline, but remain detectable, over several months (25–29).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853 · cited 6×
“Moreover, this assay has been successfully applied for analysis of convalescent plasma samples and in a campaign to identify potent human monoclonal antibodies [6, 7].”
BackgroundMethodResultInfluentialSelf-citationRobust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308
Self-citationRobust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
(2020) · Science · doi:10.1101/2020.07.14.20151126 · Cited by 1,192
Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19
Ibarrondo, F. J., Fulcher, J. A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M. A., Ferbas, K. G., Tobin, N. H., Aldrovandi, G. M., & Yang, O. O. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2025179 · Cited by 1,021 · cited 1×
“Recent reports have similarly indicated that SARS-CoV-2 neutralizing antibody titers decline with time [23, 24], while another study reported that neutralization titers remained stable for ≥3 months after infection [30].”
ResultBarnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795 · cited 5×
“The S1/S2-based DiaSorin assay was the best predictor of NT50 (r = 0.84; P < .001) (Figure 3A), followed by the RBD-based Siemens assay (r = 0.74; P < .001) (Figure 3B), the N-based Abbott assay (r = 0.69; P < .001) (Figure 3C) and, finally, the Roche assay (r = 0.56; P = .001) (Figure 3D).”
InfluentialSelf-citationSeasonal coronavirus protective immunity is short-lasting
Edridge, A. W. D., Kaczorowska, J., Hoste, A. C. R., Bakker, M., Klein, M., Loens, K., Jebbink, M. F., Matser, A., Kinsella, C. M., Rueda, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1083-1 · Cited by 767 · cited 1×
“However, human CoV reinfections occur [34, 35], often within 12 months [35], but with more mild illness.”
BackgroundTo, K. K.-W., Hung, I. F.-N., Ip, J. D., Chu, A. W.-H., Chan, W.-M., Tam, A. R., Fong, C. H.-Y., Yuan, S., Tsoi, H.-W., Ng, A. C.-K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1275 · Cited by 746
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598 · cited 2×
“High levels of circulating neutralizing antibody correlated with protection from reinfection [33, 34].”
BackgroundMeasuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572
Self-citationBryan, A., Pepper, G., Wener, M. H., Fink, S. L., Morishima, C., Chaudhary, A., Jerome, K. R., Mathias, P. C., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00941-20 · Cited by 527
Enhanced SARS-CoV-2 neutralization by dimeric IgA
Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffmann, H.-H., Oliveira, T. Y., Oren, D. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1555 · Cited by 475
Self-citationSerology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset
Lou, B., Li, T.-D., Zheng, S.-F., Su, Y.-Y., Li, Z.-Y., Liu, W., Yu, F., Ge, S.-X., Zou, Q.-D., Yuan, Q., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00763-2020 · Cited by 472 · cited 1×
“Notably our study is one of the few that would capture this information, as most other studies have examined seroconversion at early time points(14, 18-20).”
ResultHumoral and circulating follicular helper T cell responses in recovered patients with COVID-19
Juno, J. A., Tan, H.-X., Lee, W. S., Reynaldi, A., Kelly, H. G., Wragg, K., Esterbauer, R., Kent, H. E., Batten, C. J., Mordant, F. L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0995-0 · Cited by 437
Klein, S. L., Pekosz, A., Park, H.-S., Ursin, R. L., Shapiro, J. R., Benner, S. E., Littlefield, K., Kumar, S., Naik, H. M., Betenbaugh, M. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142004 · Cited by 432
Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infectionPreprint
Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K., Hemmings, O., O'Bryne, A., Kouphou, N., Pickering, S., Rui, G.-L. P., et al. (2020) · medRxiv · doi:10.1101/2020.07.09.20148429 · Cited by 411 · cited 1×
“Recent reports have similarly indicated that SARS-CoV-2 neutralizing antibody titers decline with time [23, 24], while another study reported that neutralization titers remained stable for ≥3 months after infection [30].”
ResultSystemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
Cervia, C., Nilsson, J., Zurbuchen, Y., Valaperti, A., Schreiner, J., Wolfensberger, A., Raeber, M. E., Adamo, S., Weigang, S., Emmenegger, M., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.10.040 · Cited by 408
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
GeurtsvanKessel, C. H., Okba, N. M. A., Igloi, Z., Bogers, S., Embregts, C. W. E., Laksono, B. M., Leijten, L., Rokx, C., Rijnders, B., Rahamat-Langendoen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17317-y · Cited by 361
Kellam, P., & Barclay, W. (2020) · Journal of General Virology · doi:10.1099/jgv.0.001439 · Cited by 351 · cited 1×
“For SARS-CoV and Middle East respiratory syndrome (MERS) CoV, antibody responses also decline in the majority of infected individuals [36] Indeed, analyses of the decay of SARS-CoV antibodies indicate kinetics consistent with those reported herein [37].”
ResultRobust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.29.174888 · Cited by 272
Gallais, F., Velay, A., Nazon, C., Wendling, M.-J., Partisani, M., Sibilia, J., Candon, S., & Fafi-Kremer, S. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2701.203611 · Cited by 267
Van Elslande, J., Vermeersch, P., Vandervoort, K., Wawina-Bokalanga, T., Vanmechelen, B., Wollants, E., Laenen, L., André, E., Van Ranst, M., Lagrou, K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1330 · Cited by 238
Wajnberg, A., Mansour, M., Leven, E., Bouvier, N. M., Patel, G., Firpo-Betancourt, A., Mendu, R., Jhang, J., Arinsburg, S., Gitman, M., et al. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30120-8 · Cited by 222
MO, H., ZENG, G., REN, X., LI, H., KE, C., TAN, Y., CAI, C., LAI, K., CHEN, R., CHAN‐YEUNG, M., et al. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00783.x · Cited by 193 · cited 1×
“For SARS-CoV and Middle East respiratory syndrome (MERS) CoV, antibody responses also decline in the majority of infected individuals [36] Indeed, analyses of the decay of SARS-CoV antibodies indicate kinetics consistent with those reported herein [37].”
ResultThe dominance of human coronavirus OC43 and NL63 infections in infants
Dijkman, R., Jebbink, M. F., Gaunt, E., Rossen, J. W. A., Templeton, K. E., Kuijpers, T. W., & van der Hoek, L. (2012) · Journal of Clinical Virology · doi:10.1016/j.jcv.2011.11.011 · Cited by 190
Self-citationLuchsinger, L. L., Ransegnola, B. P., Jin, D. K., Muecksch, F., Weisblum, Y., Bao, W., George, P. J., Rodriguez, M., Tricoche, N., Schmidt, F., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02005-20 · Cited by 187 · cited 5×
“Moreover, this assay has been successfully applied for analysis of convalescent plasma samples and in a campaign to identify potent human monoclonal antibodies [6, 7].”
InfluentialSelf-citationPerformance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
Jääskeläinen, A., Kuivanen, S., Kekäläinen, E., Ahava, M., Loginov, R., Kallio-Kokko, H., Vapalahti, O., Jarva, H., Kurkela, S., & Lappalainen, M. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104512 · Cited by 181 · cited 1×
“A number of high-throughput commercial assays have been deployed for SARS-CoV-2 antibody testing and evaluated mostly using hospitalized participants [9, 10].”
MethodRijkers, G., Murk, J.-L., Wintermans, B., van Looy, B., van den Berge, M., Veenemans, J., Stohr, J., Reusken, C., van der Pol, P., & Reimerink, J. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa463 · Cited by 176
Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain.
Elslande, J. V., Vermeersch, P., Vandervoort, K., Wawina-Bokalanga, T., Vanmechelen, B., Wollants, E., Laenen, L., André, E., Ranst, M. A. V., Lagrou, K., et al. (2020) · Clinical Infectious Diseases · Cited by 133
Dogan, M., Kozhaya, L., Placek, L., Gunter, C., Yiğit, M., Hardy, R., Plassmeyer, M. L., Coatney, P., Lillard, K., Bukhari, Z., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01649-6 · Cited by 131
Callow, K. A. (1985) · Journal of Hygiene · doi:10.1017/s0022172400062410 · Cited by 119
Perkmann, T., Perkmann‐Nagele, N., Breyer, M., Breyer‐Kohansal, R., Burghuber, O. C., Hartl, S., Aletaha, D., Sieghart, D., Quehenberger, P., Marculescu, R., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa198 · Cited by 118 · cited 1×
“8 days after PCR testing) that were comparable to those reported using hospitalized patients [16].”
ResultIntrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without SeroconversionPreprint
Gallais, F., Velay, A., Wendling, M.-J., et al. (2020) · medRxiv · doi:10.1101/2020.06.21.20132449 · Cited by 111
Pickering, S., Betancor, G., Galão, R. P., Merrick, B., Signell, A. W., Wilson, H. D., Kia Ik, M. T., Seow, J., Graham, C., Acors, S., et al. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008817 · Cited by 107
Wajnberg, A., Mansour, M., Leven, E. A., et al. (2020) · medRxiv · doi:10.1101/2020.04.30.20085613 · Cited by 105 · cited 1×
“Nevertheless, the vast majority of individuals with a PCR-confirmed SARSCoV-2 infection generate antibodies at a sufficient level for diagnosis of recent infection [8].”
BackgroundMethods and recommendations for evaluating and reporting a new diagnostic test
Hess, A. S., Shardell, M. D., Johnson, J. K., Thom, K. A., Strassle, P. D., Netzer, G., & Harris, A. D. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1602-1 · Cited by 104 · cited 1×
“Therefore, S-based assays may be preferable to N-based assays for assessing future reinfection risk [4].”
MethodA Case of Early Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Larson, D., Brodniak, S. L., Voegtly, L. J., Cer, R. Z., Glang, L. A., Malagon, F. J., Long, K. A., Potocki, R., Smith, D. R., Lanteri, C., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1436 · Cited by 93 · cited 1×
“Moreover, recent studies have documented SARS-CoV-2 reinfection (39-41), in one case in the context of waning neutralizing antibodies (42).”
SARS-CoV-2 antibody testing—questions to be asked
Özcürümez, M. K., Ambrosch, A., Frey, O., Haselmann, V., Holdenrieder, S., Kiehntopf, M., Neumaier, M., Walter, M., Wenzel, F., Wölfel, R., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.020 · Cited by 86 · cited 3×
“This premise is based on the assumptions (1) that neutralizing antibodies constitute a major mechanism of protective immunity, and (2) that S-based serology assays accurately predict neutralizing activity.”
BackgroundInfluentialSystemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19Preprint
Cervia, C., Nilsson, J., Zurbuchen, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.21.108308 · Cited by 78
IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Staines, H. M., Kirwan, D. E., Clark, D. J., Adams, E. R., Augustin, Y. S., Byrne, R. L., Cocozza, M., Cubas-Atienzar, A. I., Cuevas, L. E., Cusinato, M., et al. (2020) · Emerging infectious diseases · doi:10.3201/eid2701.203074 · Cited by 78
Macnaughton, M. R. (1982) · Infection and Immunity · doi:10.1128/iai.38.2.419-423.1982 · Cited by 67 · cited 1×
“Many adults possess circulating antibodies to seasonal human coronaviruses (CoVs) OC43 and 229E [31], and children seroconvert to NL63 and 229E before about 3.”
BackgroundSerum Antibody Profile of a Patient With Coronavirus Disease 2019 Reinfection
To, K. K., Hung, I. F., Chan, K., Yuan, S., To, W., Tsang, D. N., Cheng, V. C., Chen, Z., Kok, K., & Yuen, K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1368 · Cited by 62 · cited 1×
“Moreover, recent studies have documented SARS-CoV-2 reinfection [38–40], in one case in the context of waning neutralizing antibodies [41].”
BackgroundDynamics of IgG seroconversion and pathophysiology of COVID-19 infectionsPreprint
Staines, H. M., Kirwan, D. E., Clark, D. J., et al. (2020) · medRxiv · doi:10.1101/2020.06.07.20124636 · Cited by 48
Humoral Response Dynamics Following Infection with SARS-CoV-2
Grandjean, L., Saso, A., Torres, A., Lam, T., Hatcher, J., Thistlethwayte, R., Harris, M., Best, T., Johnson, M., Wagstaffe, H., et al. (2020) · medRxiv · doi:10.1101/2020.07.16.20155663 · Cited by 45 · cited 1×
“Although other studies have reported an inherent difference in the dynamics of S versus N antibodies [21] our findings do not support this contention, during the first 100 days or so of convalescence.”
ResultEnhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro
Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffman, H.-H., Oliveira, T. Y., Oren, D. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.09.288555 · Cited by 35 · cited 1×
“Neutralization is not specific for any antibody isotype or subclass, and neutralizing titers will reflect the combined activity of all neutralizing antibodies in a sample, Again the comparative stability of the IgG response and the dominant role of IgG in neutralizing plasma [29] do not comport with the idea that chan…”
BackgroundSelf-citationDogan, M., Kozhaya, L., Placek, L., et al. (2020) · medRxiv · doi:10.1101/2020.07.07.20148106 · Cited by 32
Rapid roll out of SARS-CoV-2 antibody testing—a concern
Andersson, M., Low, N., French, N., Greenhalgh, T., Jeffery, K., Brent, A., Ball, J., Pollock, A., McCoy, D., Iturriza-Gomara, M., et al. (2020) · BMJ · doi:10.1136/bmj.m2420 · Cited by 31 · cited 1×
“The prognostic value of antibody measurements with respect to reinfection has yet to be applyparastyle “fig//caption/p[1]” parastyle “FigCapt””
BackgroundPerkmann, T., Perkmann‐Nagele, N., Breyer, M., et al. (2020) · medRxiv · doi:10.1101/2020.06.04.20117911 · Cited by 25
Differences in antibody kinetics and functionality between severe and mild SARS-CoV-2 infectionsPreprint
Rijkers, G. T., Murk, J., Wintermans, B., et al. (2020) · medRxiv · doi:10.1101/2020.06.09.20122036 · Cited by 24
Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donorsPreprint
Perreault, J., Tremblay, T., Fournier, M., Drouin, M., Beaudoin-Bussières, G., Prévost, J., Lewin, A., Bégin, P., Finzi, A., & Bazin, R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.16.206847 · Cited by 12 · cited 1×
“12 of the same or related antigens can differ(22-25).”
BackgroundGroup, T. N. S.-C.-2. S. A. E. G. T. N. S.-C.-2. S. A. E. (2020) · Figshare · doi:10.6084/m9.figshare.c.5046032 · Cited by 2
Cited by
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Self-citationSeow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940
Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 “long haulers”
Graham, E. L., Clark, J. R., Orban, Z. S., Lim, P. H., Szymanski, A. L., Taylor, C., DiBiase, R. M., Jia, D. T., Balabanov, R., Ho, S. U., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51350 · Cited by 693
Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E. J. M., Simmons, R., Wellington, E., Cole, M. J., Saei, A., Oguti, B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00675-9 · Cited by 638
Self-citation
Metadata
- Authors
- Muecksch, F., Wise, H., Batchelor, B., Squires, M., Semple, E., Richardson, C., McGuire, J., Clearly, S., Furrie, E., Greig, N., Hay, G., Templeton, K., Lorenzi, J. C. C., Hatziioannou, T., Jenks, S., & Bieniasz, P. D.
- Affiliations
- Rockefeller University (US)
- NHS Lothian (GB)
- NHS Lanarkshire (GB)
- NHS Tayside (GB)
- Laboratory of Retrovirology, The Rockefeller University, New York, New York, USA
- Howard Hughes Medical Institute (US)
- Corresponding author
- Bieniasz, Paul D
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-03
- Volume
- 223
- Issue
- 3
- Pages
- 389-398
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC7665595
- OpenAlex
- W3096243826
- Cited by
- 308
- References
- 60
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 15 · 2023: 37 · 2022: 73 · 2021: 147 · 2020: 20
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Infectious Diseases (publishedVersion, cc-by-nc-nd)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI078788, R37AI064003)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, serological assays, antibody titers, spike protein antigen, antibody waning, reinfection, convalescent patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.